Abstract CT238: Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance)
Year: 2014
Type: conference-abstract
Source: Cancer Research
Institutions: University of New Mexico, New Mexico Cancer Center, UNM Comprehensive Cancer Center, Duke University, Roswell Park Comprehensive Cancer Center, Washington University in St. Louis, Illinois CancerCare, SUNY Upstate Medical University, The Ohio State University Wexner Medical Center, City Of Hope National Medical Center, Mayo Clinic, The University of Texas Southwestern Medical Center, Yale University, University of Chicago, University of Minnesota
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1997960768